Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
This article was originally published in PharmAsia News
Executive Summary
Already cleared for gastroesophageal reflux disease in adults, Eisai's Aciphex won U.S. FDA clearance June 30 for short-term use by adolescents age 12 and higher
You may also be interested in...
Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex
TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S
Eisai Wins Patent Lawsuit For Proton Pump Inhibitor AcipHex
TOKYO - In a decision that would bolster its underlying profit-making structure and spur its intellectual property protection policy, Eisai July 22 said it won a patent lawsuit for its proton pump inhibitor AcipHex, one of its two leading global pharmaceutical products, in the U.S
Eisai Posts First Ever Net Loss Due To Heavy Investment
TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961